O
ORIC Pharmaceuticals
Biotech & Life Sciences · San Francisco, United States · Founded 2014 · IPO 2020
ORIC Pharmaceuticals Inc operates as a biopharmaceutical company MoreLess
ORIC Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies to overcome resistance in cancer treatment. The company's lead product candidate, ORIC-101, is a glucocorticoid receptor (GR) antagonist currently in Phase 1b clinical trials. GR is often overexpressed in multiple solid tumors and is associated with poorer outcomes, making it a critical target for cancer therapy. By blocking GR activity, ORIC-101 aims to improve patient outcomes and combat resistance to existing treatments.
ORIC Pharmaceuticals operates in the oncology market, primarily serving patients with advanced or metastatic solid tumors. The company employs a research-driven business model, investing heavily in preclinical and clinical trials to validate its therapeutic candidates. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies.
The company is also exploring other promising candidates, such as a CD73 inhibitor, to further expand its pipeline. ORIC Pharmaceuticals aims to address significant unmet medical needs in oncology by targeting the underlying mechanisms of resistance.
Keywords: oncology, cancer treatment, resistance mechanisms, glucocorticoid receptor, GR antagonist, ORIC-101, clinical trials, biopharmaceutical, CD73 inhibitor, metastatic tumors.
Company overview
ORIC Pharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2014
- Headquarters
- San Francisco, United States
- Employees
- 137
- Open positions
- 4
- Dealroom signal
- 74.2
Valuation & funding
ORIC Pharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Feb 2026 | $264M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | May 2025 | $125M | — | NEA · SR One · Viking Global Investors · Nextech | ↗ |
| POST IPO EQUITYOther financing | Feb 2024 | $4.7M | — | Vivo Capital | ↗ |
| POST IPO EQUITYOther financing | Jun 2023 | $85M | — | Tavistock Group · Frazier Healthcare Partners · Nextech Invest · EcoR1 Capital | ↗ |
| POST IPO EQUITYOther financing | Dec 2022 | $25M | — | Pfizer | ↗ |
| IPOOther financing | Apr 2020 | Undisclosed | — | ||
| SERIES DOther financing | Aug 2019 | The Column Group · Casdin Capital · Memorial Sloan - Kettering Cancer Center · City Hill Ventures | — | ||
| SERIES COther financing | Feb 2018 | Fidelity Investments | — | ||
| SERIES BOther financing | Dec 2015 | Undisclosed | — | ||
| SERIES AOther financing | Nov 2014 | The Column Group | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$165M | — |
| 2025 | $0 | — | −$142M | — |
| 2024 | $0 | — | −$142M | — |
| 2023 | $0 | — | −$110M | — |
| 2022 | $0 | — | −$82M | — |
| 2021 | $0 | — | −$79M | — |
| 2020 | $0 | — | −$25M | — |
Growth signals
ORIC Pharmaceuticals website traffic
Latest recorded traffic for ORIC Pharmaceuticals is 6.8K monthly website visits, up 30.8% over the last three months. ORIC Pharmaceuticals's team grew 6.2% over the past year.
Hiring
Open positions at ORIC Pharmaceuticals
Current openings linked to this company in Dealroom.
Comparisons
ORIC Pharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
ORIC Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where ORIC Pharmaceuticals has talent and traffic
team presence
In the news
Latest news about ORIC Pharmaceuticals
Recent press, funding announcements, and product moves mentioning ORIC Pharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about ORIC Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about ORIC Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ORIC Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.